A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

NCT01954043 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: Dabrafenib 150 mg twice a day (BID)
DRUG: Rabeprazole 40 mg once daily (OD)
DRUG: Rifampin 600 mg OD

Sponsor

GlaxoSmithKline